NZ603482A - Bioactive renal cells - Google Patents

Bioactive renal cells

Info

Publication number
NZ603482A
NZ603482A NZ603482A NZ60348211A NZ603482A NZ 603482 A NZ603482 A NZ 603482A NZ 603482 A NZ603482 A NZ 603482A NZ 60348211 A NZ60348211 A NZ 60348211A NZ 603482 A NZ603482 A NZ 603482A
Authority
NZ
New Zealand
Prior art keywords
renal cells
bioactive renal
medicament
subject
human
Prior art date
Application number
NZ603482A
Other languages
English (en)
Inventor
Oluwatoyin A Knight
Kelly I Guthrie
Sharon C Presnell
Christopher W Genheimer
Namrata D Sangha
Joydeep Basu
Roger M Ilagan
Benjamin Watts
Richard Payne
Manuel J Jayo
Thomas Spencer
Neil F Robins Jr
Andrew T Bruce
Elias A Rivera
Sumana Choudhury
Craig R Halberstadt
Shay M Wallace
Darrell Mccoy
John W Ludlow
Eric S Werdin
Russell W Keller
Deepak Jain
Bryan R Cox
Original Assignee
Tengion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tengion Inc filed Critical Tengion Inc
Publication of NZ603482A publication Critical patent/NZ603482A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ603482A 2010-05-12 2011-05-12 Bioactive renal cells NZ603482A (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US33403210P 2010-05-12 2010-05-12
US35389510P 2010-06-11 2010-06-11
US37207710P 2010-08-09 2010-08-09
US37188810P 2010-08-09 2010-08-09
US37658610P 2010-08-24 2010-08-24
US38876510P 2010-10-01 2010-10-01
US41293310P 2010-11-12 2010-11-12
US41338210P 2010-11-12 2010-11-12
US201161441423P 2011-02-10 2011-02-10
US201161473111P 2011-04-07 2011-04-07
PCT/US2011/036347 WO2011143499A1 (en) 2010-05-12 2011-05-12 Bioactive renal cells

Publications (1)

Publication Number Publication Date
NZ603482A true NZ603482A (en) 2014-11-28

Family

ID=44121234

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ603482A NZ603482A (en) 2010-05-12 2011-05-12 Bioactive renal cells

Country Status (14)

Country Link
US (4) US10077442B2 (https=)
EP (3) EP3190177B8 (https=)
JP (6) JP5974215B2 (https=)
KR (5) KR102539589B1 (https=)
CN (2) CN103154236B (https=)
AU (5) AU2011252915B2 (https=)
CA (1) CA2798900C (https=)
DK (1) DK3190177T3 (https=)
ES (1) ES2906750T3 (https=)
HU (1) HUE058155T2 (https=)
NZ (1) NZ603482A (https=)
PL (1) PL3190177T3 (https=)
TW (6) TWI762890B (https=)
WO (1) WO2011143499A1 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US20090104649A1 (en) 2007-06-11 2009-04-23 Garovic Vesna D Markers for preeclampsia
US20130034861A1 (en) 2009-12-21 2013-02-07 Mayo Foundation For Medical Education And Research Early marker of proteinuria in patients treated with an anti-vegf treatment
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
TWI762890B (zh) 2010-05-12 2022-05-01 開曼群島商英瑞金公司 生物活性腎細胞
CA3065694A1 (en) 2010-11-10 2012-05-18 Inregen Methods of forming injectable formulations for providing regenerative effects to an organ such as a kidney
WO2013170146A1 (en) 2012-05-10 2013-11-14 Uab Research Foundation Methods and compositions for modulating mir-204 activity
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
AU2013302799B2 (en) 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
RU2702721C2 (ru) * 2012-10-24 2019-10-09 инРиджен Популяции клеток почек и их применение
EP4299721A3 (en) * 2013-05-08 2024-04-24 ProKidney Organoids comprising isolated renal cells and uses thereof
US20170003299A1 (en) * 2013-11-27 2017-01-05 Mayo Foundation For Medical Education And Research Detecting podocyte injury in diabetic nephropathy and glomerulonephritis
CN109207580B (zh) 2014-03-12 2022-03-11 西奈山伊坎医学院 鉴定处于慢性损伤风险的肾异体移植物接受者的方法
US10308985B2 (en) 2014-06-26 2019-06-04 Icahn School Of Medicine At Mount Sinai Methods for diagnosing risk of renal allograft fibrosis and rejection
WO2015200887A2 (en) 2014-06-26 2015-12-30 Icahn School Of Medicine At Mount Sinai Method for diagnosing subclinical and clinical acute rejection by analysis of predictive gene sets
CN107641614B (zh) * 2014-06-30 2020-11-20 中国人民解放军军事医学科学院野战输血研究所 微囊泡在诱导干细胞巨核分化中的用途
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
WO2017058938A1 (en) 2015-09-29 2017-04-06 Research Institute At Nationwide Children's Hospital Methods for detecting hepatic fibrosis and responsiveness to therapy
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
KR102467150B1 (ko) 2016-05-06 2022-11-14 유니사이트 이브이 에이지 고혈당으로 인해 유발되는 섬유성 질환의 치료에 사용하기 위한 miRNA를 함유하는 약제학적 담체
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
US11123372B2 (en) 2016-07-29 2021-09-21 Prokidney Bioactive renal cells for the treatment of chronic kidney disease
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
KR101725025B1 (ko) * 2016-11-25 2017-04-10 서울대학교산학협력단 무형성골질환 진단용 miRNA 마커
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
EP4699658A2 (en) 2017-04-19 2026-02-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
CN107236799B (zh) * 2017-06-15 2020-06-09 昆明医科大学第六附属医院 一种肾纤维化miRNA标记物
CA3067558A1 (en) 2017-06-16 2018-12-20 Avery Therapeutics, Inc. Three dimensional tissue compositions and methods of use
BR112019027086A2 (pt) * 2017-06-21 2020-07-07 Timothy A. Bertram células renais bioativas imunoprivilegiadas para o tratamento de doença renal
US11395832B2 (en) * 2017-12-14 2022-07-26 Unicyte Ev Ag Pharmaceutical carriers containing miRNAs for use in the treatment of renal cancer
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
US12146137B2 (en) 2018-02-05 2024-11-19 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and Y-RNAS
ES3037279T3 (en) 2018-04-16 2025-09-30 Icahn School Med Mount Sinai Method and kits for prediction of acute rejection and renal allograft loss using pre-transplant transcriptomic signatures in recipient blood
TWI698640B (zh) * 2018-04-23 2020-07-11 長庚醫療財團法人高雄長庚紀念醫院 用於檢測狼瘡性腎炎或評估狼瘡性腎炎風險的方法及其應用
EP3843760A4 (en) * 2018-08-31 2022-11-09 Timothy Bertram COMPOSITIONS WITH CELL-DERIVED VESICLES AND THEIR USES
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US20210393853A1 (en) * 2018-10-29 2021-12-23 Avery Therapeutics, Inc. Compositions and methods for cryopreservation and reconstitution of engineered tissues
CN111733234A (zh) * 2019-03-25 2020-10-02 深圳大学 一种食管癌分子标志物及其应用
KR20220042117A (ko) * 2019-08-09 2022-04-04 우베 고산 가부시키가이샤 엑소좀의 생성 방법
EP4015635A4 (en) * 2019-08-16 2023-10-25 Public University Corporation Nagoya City University Colorectal cancer diagnostic marker, method for assisting diagnosis of colorectal cancer, method for collecting data for diagnosis of colorectal cancer, colorectal cancer diagnostic kit, therapeutic agent for colorectal cancer, method for treating colorectal cancer, and method for diagnosing colorectal cancer
CN110734972B (zh) * 2019-11-28 2023-06-16 河北仁博科技有限公司 miR-181c-3p作为肾纤维化标志物的应用
WO2021177387A1 (ja) * 2020-03-04 2021-09-10 株式会社メトセラ エリスロポエチン産生能が亢進された線維芽細胞
US20230212492A1 (en) * 2020-06-08 2023-07-06 National University Corporation Tokyo Medical And Dental University Cell culture method
CN112263587B (zh) * 2020-10-23 2022-08-30 河北仁博科技有限公司 miR-3065-5p在制备预防和/或治疗肾纤维化的药物中的应用
CN112760376B (zh) * 2020-12-30 2021-12-07 陈晓熠 miRNA-3918在非小细胞肺癌检测中的应用
WO2023107698A1 (en) * 2021-12-09 2023-06-15 Encellin, Inc. Methods and devices for pre-vascularization of implantation sites and/or cell encapsulation devices
CN115976211A (zh) * 2022-12-09 2023-04-18 深圳市科芮达健康科技有限公司 血液microRNA作为尿路上皮癌筛查或诊断标志物的用途、检测引物和试剂盒
CN116240161B (zh) * 2023-02-27 2024-05-10 四川大学华西医院 具有肾脏损伤修复作用的细胞外囊泡制备方法及应用
CN117853729B (zh) * 2024-01-10 2025-09-30 清华大学深圳国际研究生院 一种基于深度学习的多切面层次肾小球识别和匹配方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032508A (en) 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US5863531A (en) 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
CN1053698C (zh) 1989-01-19 2000-06-21 南京大学 细胞培养生产促红细胞生成素的方法
DE69017820T2 (de) 1989-04-25 1995-10-05 Children's Medical Center Corp., Boston, Mass. Implantaten für grosse mengen von zellen auf polymerische matrizen.
AU2900792A (en) 1991-10-24 1993-05-21 Children's Medical Center Corporation Neomorphogenesis of urological structures in vivo from cell culture
US5549674A (en) 1992-03-02 1996-08-27 The Regents Of The University Of Michigan Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US6224893B1 (en) 1997-04-11 2001-05-01 Massachusetts Institute Of Technology Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering
JP2004155788A (ja) * 1998-09-24 2004-06-03 Tanabe Seiyaku Co Ltd 腎疾患治療薬およびそのスクリーニング方法
WO2000073791A1 (fr) 1999-05-27 2000-12-07 Tanabe Seiyaku Co., Ltd. Remedes pour affections renales et procede de criblage de tels medicaments
KR100369788B1 (ko) 1999-09-03 2003-01-29 동아제약 주식회사 재조합 인간 에리트로포이에틴의 제조방법
WO2002061053A1 (en) 2001-01-31 2002-08-08 The General Hospital Corporation Renal stem cells and uses thereof
BR0214217A (pt) 2001-11-16 2004-09-21 Childrens Medical Center Aumento de função de órgão
WO2003080038A1 (en) 2002-03-22 2003-10-02 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for kidney disease
JP2004309186A (ja) * 2003-04-02 2004-11-04 Tokai Univ 小胞体ストレスの改善剤およびその評価方法
AU2004249812B8 (en) 2003-06-25 2011-09-15 Ottawa Hospital Research Institute Methods and compositions for modulating stem cell growth and differentiation
US20070196269A1 (en) * 2003-12-19 2007-08-23 Karl-Hermann Schlingensiepen Pharmaceutical composition
WO2007035843A2 (en) 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
US20070104799A1 (en) 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
US7850983B2 (en) 2006-02-07 2010-12-14 Spinalcyte, Llc Methods and compositions for repair of cartilage using an in vivo bioreactor
CA2871840A1 (en) 2006-02-10 2007-08-23 Tengion, Inc. Scaffolds for organ reconstruction and augmentation
WO2007125916A1 (ja) 2006-04-24 2007-11-08 Stemcell Institute Inc. 移植用臓器の調製方法
US8758991B2 (en) * 2006-04-26 2014-06-24 University Of Louisville Research Foundation, Inc. Isolation of membrane vesicles from biological fluids and methods of using same
CN101595212B (zh) 2006-10-12 2014-04-30 伊西康公司 肾源细胞及在组织修复和再生中的使用方法
AU2007319214B2 (en) 2006-11-16 2014-04-17 Genentech, Inc. Genetic variations associated with tumors
US20110008347A1 (en) 2006-12-01 2011-01-13 Agency For Science ,Technology And Research Cancer-related protein kinases
US7924332B2 (en) 2007-05-25 2011-04-12 The Trustees Of The University Of Pennsylvania Current/voltage mode image sensor with switchless active pixels
US10590391B2 (en) 2007-06-08 2020-03-17 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
CN101827933B (zh) 2007-06-08 2014-01-29 韦克福里斯特大学健康科学院 治疗肾功能衰竭的选择性细胞疗法
US9580688B2 (en) 2007-06-08 2017-02-28 Wake Forest University Health Sciences Kidney structures and methods of forming the same
DE102007033074A1 (de) * 2007-07-13 2009-01-15 Pac Tech-Packaging Technologies Gmbh Verfahren und Vorrichtung zur Entfernung von Lotmaterialdepots von einem Substrat
ES2523098T3 (es) 2007-10-29 2014-11-20 Fresenius Medical Care Deutschland Gmbh Microvesícula (MV) derivada de células madre para su uso en la inhibición de la apoptosis inducida por un agente citostático
EP2067785A1 (en) 2007-12-03 2009-06-10 Fresenius Medical Care Deutschland GmbH Human CD154-binding synthetic peptide and uses thereof
CA2711878A1 (en) * 2008-01-09 2009-07-16 Intrexon Corporation Therapeutic inhibitors of pai-1 function and methods of their use
EP2245199B1 (en) 2008-02-01 2013-11-13 The General Hospital Corporation Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
WO2010014643A1 (en) * 2008-07-28 2010-02-04 Virginia Tech Intellectual Properties, Inc. Irak-1 as regulator of diseases and disorders
EP2186883A1 (en) 2008-11-04 2010-05-19 Fresenius Medical Care An isolated multipotent mesenchymal stem cell from human adult glomeruli (hGL-MSC), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney
KR102428795B1 (ko) 2008-11-12 2022-08-04 인리젠 분리된 신장 세포 및 이의 용도
JP5565607B2 (ja) 2009-07-15 2014-08-06 国立大学法人 東京大学 敗血症又は多臓器不全の予後診断方法及び予後診断用キット
EP2333047A1 (en) 2009-12-09 2011-06-15 Fresenius Medical Care Deutschland GmbH Adult stem cell derived conditioned medium and/or adult stem cells for use in the therapeutic treatment of a tumor disease
EP2363136A1 (en) 2010-03-02 2011-09-07 Fresenius Medical Care Deutschland GmbH Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease
TWI762890B (zh) 2010-05-12 2022-05-01 開曼群島商英瑞金公司 生物活性腎細胞
JP5755326B2 (ja) 2010-06-11 2015-07-29 日立化成株式会社 腎機能の特徴を決定する方法
CA3065694A1 (en) 2010-11-10 2012-05-18 Inregen Methods of forming injectable formulations for providing regenerative effects to an organ such as a kidney
EP3083941B1 (en) 2013-12-16 2023-02-22 Fresenius Medical Care Deutschland GmbH Pancreatic islet-like cell structures and a method of preparing thereof
JP2019518428A (ja) 2016-04-12 2019-07-04 ユニシテ エーファウ アクチェンゲゼルシャフト 体液試料からの細胞外小胞（ｅｖ）の単離
KR102467150B1 (ko) 2016-05-06 2022-11-14 유니사이트 이브이 에이지 고혈당으로 인해 유발되는 섬유성 질환의 치료에 사용하기 위한 miRNA를 함유하는 약제학적 담체

Also Published As

Publication number Publication date
EP2569418A1 (en) 2013-03-20
JP2013528375A (ja) 2013-07-11
JP6744368B2 (ja) 2020-08-19
JP7123426B2 (ja) 2022-08-23
ES2906750T3 (es) 2022-04-20
TWI898523B (zh) 2025-09-21
US20210238600A1 (en) 2021-08-05
AU2011252915A1 (en) 2012-11-29
CN103154236B (zh) 2016-08-31
JP2016208963A (ja) 2016-12-15
JP2020201266A (ja) 2020-12-17
KR101975212B1 (ko) 2019-05-07
TW202228737A (zh) 2022-08-01
TWI629990B (zh) 2018-07-21
JP2022153631A (ja) 2022-10-12
EP3190177A1 (en) 2017-07-12
US20240409941A1 (en) 2024-12-12
KR20180027604A (ko) 2018-03-14
JP5974215B2 (ja) 2016-08-24
KR101834830B1 (ko) 2018-04-19
US12157887B2 (en) 2024-12-03
AU2020203727A1 (en) 2020-06-25
AU2018200761A1 (en) 2018-02-22
TWI762890B (zh) 2022-05-01
US11066666B2 (en) 2021-07-20
NZ809978A (en) 2025-07-25
KR20190047141A (ko) 2019-05-07
TWI690320B (zh) 2020-04-11
EP4083191A1 (en) 2022-11-02
JP2018203746A (ja) 2018-12-27
JP6385976B2 (ja) 2018-09-05
US10077442B2 (en) 2018-09-18
TW201211255A (en) 2012-03-16
EP3190177B1 (en) 2022-01-12
PL3190177T3 (pl) 2022-06-06
NZ796266A (en) 2024-04-26
AU2011252915B2 (en) 2016-05-19
KR20130064753A (ko) 2013-06-18
WO2011143499A1 (en) 2011-11-17
KR102428776B1 (ko) 2022-08-04
JP2024056860A (ja) 2024-04-23
CN106214700B (zh) 2021-09-07
CA2798900A1 (en) 2011-11-17
EP2569418B1 (en) 2016-11-02
KR102223564B1 (ko) 2021-03-05
AU2023202707A1 (en) 2023-05-18
DK3190177T3 (da) 2022-01-31
EP3190177B8 (en) 2022-07-27
TWI840787B (zh) 2024-05-01
TW201902494A (zh) 2019-01-16
KR102539589B1 (ko) 2023-06-01
CA2798900C (en) 2021-10-12
AU2023202707B2 (en) 2026-04-09
JP7442852B2 (ja) 2024-03-05
US20160244751A1 (en) 2016-08-25
HUE058155T2 (hu) 2022-07-28
TW202532092A (zh) 2025-08-16
AU2016216646A1 (en) 2016-09-01
CN106214700A (zh) 2016-12-14
KR20220112863A (ko) 2022-08-11
TWI542690B (zh) 2016-07-21
CN103154236A (zh) 2013-06-12
KR20210024686A (ko) 2021-03-05
HK1232143A1 (zh) 2018-01-05
TW201700106A (zh) 2017-01-01
TW202027762A (zh) 2020-08-01
AU2016216646B2 (en) 2017-11-09
US20180282726A1 (en) 2018-10-04
AU2020203727B2 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
NZ603482A (en) Bioactive renal cells
IL294095B1 (en) Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
MY173215A (en) Acetylcysteine compositions and methods of use thereof
MX354702B (es) Metodo de produccion de niveles fisiologicos y terapeuticos de oxido nitrico por medio de un sistema de suministro oral.
NZ594056A (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
WO2014108571A3 (en) Cancer drug and uses
IL244945B (en) Cationic lipid, lipid formulations comprising same and use thereof in the preparation of therapeutic agents for delivering to cells
IL208992A (en) Use of h2 relaxin active pharmacist in the manufacture of drugs for the treatment of shortness of breath related to acute heart failure and decompensatory acute heart failure
WO2009124266A3 (en) Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
MX2019000382A (es) Microparticulas de polimero y proteina.
MY165086A (en) Formulations of rifaximin and uses thereof
MX2014001073A (es) Sistema y metodo personalizable para anestesiar la membrana timpanica.
WO2013090523A3 (en) Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery
CO6592015A2 (es) Métodos y composiciones para reducir o prevenir la cladificación vascular durante el tratamiento de diálisis peritoneal
IL251543A0 (en) Use of a topical gel composition in the manufacture of a medicament for the prevention or treatment of a skin disorder
WO2012047951A3 (en) Human lung stem cells and uses thereof
WO2013158258A8 (en) Ocular therapeutics using embryonic stem cell microvesicles
WO2014127232A3 (en) Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy
CA2780119A1 (en) Capsule for oral pet medicine
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
WO2011103586A3 (en) Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine
WO2013121300A3 (en) Methods for treating psoriasis and vascular inflammation
WO2011156715A3 (en) Methods of treating metabolic disorders and cardiovascular diseases
IN2014DN10134A (https=)
UA62758U (ru) Препарат "аромадент плюс" в виде геля для лечения и профилактики воспалительных заболеваний пародонта

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAY 2016 BY CPA GLOBAL

Effective date: 20150605

ASS Change of ownership

Owner name: REGENMEDTX, LLC, US

Effective date: 20151015

ASS Change of ownership

Owner name: REGENMED (CAYMAN) LTD, KY

Effective date: 20160407

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAY 2017 BY CPA GLOBAL

Effective date: 20160405

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAY 2018 BY CPA GLOBAL

Effective date: 20170331

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAY 2019 BY CPA GLOBAL

Effective date: 20180329

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAY 2020 BY CPA GLOBAL

Effective date: 20190329

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAY 2021 BY CPA GLOBAL

Effective date: 20200326

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAY 2022 BY CPA GLOBAL

Effective date: 20210326

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAY 2023 BY CPA GLOBAL

Effective date: 20220401

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAY 2024 BY CPA GLOBAL

Effective date: 20230330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAY 2025 BY COMPUTER PACKAGES INC

Effective date: 20240417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAY 2026 BY COMPUTER PACKAGES INC

Effective date: 20250417